Hester Biosciences Limited has informed the Exchange about Transcript
HESTERBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hester Biosciences reported FY25 standalone profit growth of 17% (30% in Q4), while overall revenue appeared flat due to a one-time African pharma export in the prior year; pure divisional sales grew 12%. Consolidated profit rose 36% on the back of cost discipline and better international performance. EBITDA was up 8%. Animal Health and Pet Care combined grew 8% in Q4 and 6% in FY25, with steady demand for Goat Pox and PPR vaccines under India's National Immunization Program. Hester Africa reduced its loss to Rs. 10.2 crore from Rs. 18 crore, backed by PPR and CBPP tender wins, and management expects breakeven in about two years. Management confirmed the Avian Influenza vaccine will launch at the beginning of Q2 FY26 and guided that the H9N2 market in India alone is Rs. 80–100 crore. The fill-finish facility is expected to be capitalised by Q2 FY25, while the BSL-3 facility is awaiting BIRAC approval.
The sharp improvement in profitability, debt reduction of Rs. 32 crore, and narrowing Africa losses point to strengthening fundamentals that could support the stock, though management remained vague on capacity utilisation timelines and BSL-3 revenue potential, keeping near-term visibility limited.